Angelini Pharma and Blackstone led a $140m Series D round in GRIN Therapeutics.

Angelini Pharma, an international pharmaceutical company, and Blackstone Life Sciences, a private investment platform, led a $140m Series D round in GRIN Therapeutics, a neurodevelopmental disorders therapies developer. "Our strategic collaboration with GRIN Therapeutics, including our participation in this Series D financing and in-licensing deal for radiprodil, reflects our dedication to advancing highly innovative treatments in brain health, building on our deep therapeutic expertise in neurology and psychiatry" Jacopo Andreose, Angelini Pharma CEO.